Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) are very effective in improving glucose control in people with diabetes and achieving weight loss in subjects with overweight or obesity,17, 18 while also reducing cardiovascular adverse events in these high‐risk populations.19, 20. This evidence concerns the gene GCG and obesity disorder.